big news here boys!! new study came out last tuesday 3/13 demonstrating a more effective and accurate method of vpa+wounding delivery
https://www.sciencedirect.com/science/article/pii/S0142961218301856
however, the biggest point is that this is from dr ky choi, whom you might remember discovered ptd-dbm, which got huge press here, reddit, and in mainstream media for being the most recent "cure" for Androgenetic Alopecia when coupled with vpa and wounding, which actually creates robust new follicles (https://www.sciencedirect.com/science/article/pii/S0022202X17315555 and https://www.reddit.com/r/tressless/comments/7fax04/a_south_korean_lab_actually_discovered_the_cure/ and https://www.indy100.com/article/bal...e-wonder-drug-proteins-thinning-baldy-8071226 and https://www.hairlosstalk.com/intera...chemical-material-to-prevent-hair-loss.109920). evidently they are working on improving the wounding portion of the process.
something big is happening over in south korea boys!
edit: link to the full article: http://sci-hub.tw/https://www.sciencedirect.com/science/article/pii/S0142961218301856
some highlights:
(dmn-vpa is the proposed new delivery method)
"To evaluate the efficacy of DMN-VPA in inducing hair regrowth, we shaved the dorsal skin area of 7-week-old male mice at telogen phase and applied 50 µl of 1 M VPA either as topical VPA or as DMN-VPA once a day for 28 days (n = 7/group). To confirm whether hair regrowth was induced solely by application of VPA in these treatment groups, we included two control groups of mice treated daily with either topical control or DMN control (n = 7/group). At day 28, all mice of the DMN-VPA-treated group and two out of seven mice treated with topical VPA, showed hair regrowth (Fig. 3a). The regrown hairs uniformly covered the entire shaved region in DMN-VPA-treated mice. In contrast, in the topical VPA group, hair regrowth was mainly concentrated in the center of the shaved region (indicated by a dashed line in Fig. 3a). In both the control groups, none of the mice showed hair regrowth. These findings show that DMNVPA delivers encapsulated VPA with a high accuracy over the whole region. The effect of VPA on hair density was evaluated by quantifying the number of hair shafts/cm2 over an untreated (unshaved) region in comparison to the treated (shaved) region for each mouse to account for natural variation in hair density (n = 2/group). In topical VPA-treated mice, the shaft density was 634.5 ± 9.1 shafts/cm2 in the untreated region and 642 ± 15.5 shafts/cm2 in the treated area, a mean difference of 7.5 ± 6.3 shafts/cm2 (Fig. 3b). In the DMN-VPA group, hair shaft density differed by 35 ± 19.8 shafts/cm2 , being 648.5 ± 13.44 shafts/cm2 to 683.5 ± 6.3 shafts/cm2 in unshaved and shaved regions, respectively (Fig. 3c). Next, we compared regrown hair shaft thickness of the same type in topical VPA- and DMN-VPA-treated mice (n = 20/group). In both groups, hair shaft thickness varied widely, from 7.26 µm to 51.64 µm (Supplementary Fig. 3). However, the mean hair shaft thickness under topical VPA (19.05 ± 11.41 µm) was significantly lower than that under DMN-VPA treatment (27.15 ± 12.01 µm) (Fig. 3d). Control groups were excluded from the comparison due to the lack of hair regrowth at 28 days post experiment. Scanning electron microscopy (SEM) revealed no damage to the surface of regrown hair shafts in both treatment groups (Fig. 3e). Additionally, we sectioned the treated dorsal skin regions to compare the hair regrowth characteristics in more detail (Fig. 3f). The mice treated with DMN-VPA had the highest number of HFs among the four groups, followed by topical VPA. Histomorphometrical analysis of HFs showed that DMN-VPA treatment also promoted telogen-to-anagen transition more effectively than topical VPA (Fig. 3g). As expected, most of the HFs in both control groups remained in telogen phase at day 28. To verify that the normal epidermis properties was not damaged by DMN-VPA application, the epidermal thickness was measured for each group. The epidermis was 13.81 ± 1 µm thick on average (n = 10/group), with no significant differences between and within groups (Fig. 3h). However, due to the difference in the number of HFs in each group, the dermal thickness significantly differed (n = 10/group). The dermal thickness in the topical control group was 417.3 ± 20 µm, and it significantly increased to 563 ± 135 µm upon treatment with topical VPA. Likewise, DMN-VPA treatment significantly increased the mean dermal thickness from 505 ± 27 µm to 661 ± 103 µm (Fig. 3i). Also, the dermal thickness under DMNVPA treatment was significantly higher than that upon topical VPA application. Altogether, these data imply that DMN-VPA effectively elevates HF regrowth by accelerating telogen-toanagen transition without damaging the hair shafts or epidermis layer."
https://www.sciencedirect.com/science/article/pii/S0142961218301856
however, the biggest point is that this is from dr ky choi, whom you might remember discovered ptd-dbm, which got huge press here, reddit, and in mainstream media for being the most recent "cure" for Androgenetic Alopecia when coupled with vpa and wounding, which actually creates robust new follicles (https://www.sciencedirect.com/science/article/pii/S0022202X17315555 and https://www.reddit.com/r/tressless/comments/7fax04/a_south_korean_lab_actually_discovered_the_cure/ and https://www.indy100.com/article/bal...e-wonder-drug-proteins-thinning-baldy-8071226 and https://www.hairlosstalk.com/intera...chemical-material-to-prevent-hair-loss.109920). evidently they are working on improving the wounding portion of the process.
something big is happening over in south korea boys!
edit: link to the full article: http://sci-hub.tw/https://www.sciencedirect.com/science/article/pii/S0142961218301856
some highlights:
(dmn-vpa is the proposed new delivery method)
"To evaluate the efficacy of DMN-VPA in inducing hair regrowth, we shaved the dorsal skin area of 7-week-old male mice at telogen phase and applied 50 µl of 1 M VPA either as topical VPA or as DMN-VPA once a day for 28 days (n = 7/group). To confirm whether hair regrowth was induced solely by application of VPA in these treatment groups, we included two control groups of mice treated daily with either topical control or DMN control (n = 7/group). At day 28, all mice of the DMN-VPA-treated group and two out of seven mice treated with topical VPA, showed hair regrowth (Fig. 3a). The regrown hairs uniformly covered the entire shaved region in DMN-VPA-treated mice. In contrast, in the topical VPA group, hair regrowth was mainly concentrated in the center of the shaved region (indicated by a dashed line in Fig. 3a). In both the control groups, none of the mice showed hair regrowth. These findings show that DMNVPA delivers encapsulated VPA with a high accuracy over the whole region. The effect of VPA on hair density was evaluated by quantifying the number of hair shafts/cm2 over an untreated (unshaved) region in comparison to the treated (shaved) region for each mouse to account for natural variation in hair density (n = 2/group). In topical VPA-treated mice, the shaft density was 634.5 ± 9.1 shafts/cm2 in the untreated region and 642 ± 15.5 shafts/cm2 in the treated area, a mean difference of 7.5 ± 6.3 shafts/cm2 (Fig. 3b). In the DMN-VPA group, hair shaft density differed by 35 ± 19.8 shafts/cm2 , being 648.5 ± 13.44 shafts/cm2 to 683.5 ± 6.3 shafts/cm2 in unshaved and shaved regions, respectively (Fig. 3c). Next, we compared regrown hair shaft thickness of the same type in topical VPA- and DMN-VPA-treated mice (n = 20/group). In both groups, hair shaft thickness varied widely, from 7.26 µm to 51.64 µm (Supplementary Fig. 3). However, the mean hair shaft thickness under topical VPA (19.05 ± 11.41 µm) was significantly lower than that under DMN-VPA treatment (27.15 ± 12.01 µm) (Fig. 3d). Control groups were excluded from the comparison due to the lack of hair regrowth at 28 days post experiment. Scanning electron microscopy (SEM) revealed no damage to the surface of regrown hair shafts in both treatment groups (Fig. 3e). Additionally, we sectioned the treated dorsal skin regions to compare the hair regrowth characteristics in more detail (Fig. 3f). The mice treated with DMN-VPA had the highest number of HFs among the four groups, followed by topical VPA. Histomorphometrical analysis of HFs showed that DMN-VPA treatment also promoted telogen-to-anagen transition more effectively than topical VPA (Fig. 3g). As expected, most of the HFs in both control groups remained in telogen phase at day 28. To verify that the normal epidermis properties was not damaged by DMN-VPA application, the epidermal thickness was measured for each group. The epidermis was 13.81 ± 1 µm thick on average (n = 10/group), with no significant differences between and within groups (Fig. 3h). However, due to the difference in the number of HFs in each group, the dermal thickness significantly differed (n = 10/group). The dermal thickness in the topical control group was 417.3 ± 20 µm, and it significantly increased to 563 ± 135 µm upon treatment with topical VPA. Likewise, DMN-VPA treatment significantly increased the mean dermal thickness from 505 ± 27 µm to 661 ± 103 µm (Fig. 3i). Also, the dermal thickness under DMNVPA treatment was significantly higher than that upon topical VPA application. Altogether, these data imply that DMN-VPA effectively elevates HF regrowth by accelerating telogen-toanagen transition without damaging the hair shafts or epidermis layer."
Last edited:
